Case Report: The integration of chemoradiotherapy and immunotherapy in a patient with advanced-stage renal squamous cell carcinoma and pulmonary metastases
Renal squamous cell carcinoma (RSCC) is an uncommon malignancy, representing less than 1% of all renal cancers, and is associated with a notably poor prognosis. Surgical intervention is the primary treatment modality for early and intermediate-stage cases; however, the efficacy of combined chemoradiotherapy and immunotherapy in advanced-stage patients remains unclear. In this report, we present a case of RSCC with pulmonary metastases, wherein the patient attained disease remission following a treatment regimen comprising combined chemo-radiotherapy and immunotherapy. The patient demonstrated a progression-free survival (PFS) of 12 months and an overall survival (OS) of 14 months. This case study aims to provide a comprehensive analysis of the treatment approach, potentially serving as a reference for therapeutic strategies in patients with inoperable RSCC.
Authors
- Zhiguo Luo (ORCID: https://orcid.org/0000-0003-0389-2350)
- Xinzhou Deng (ORCID: https://orcid.org/0000-0002-9775-4604)
- Yanlin Niu (ORCID: https://orcid.org/0000-0002-4946-3028)
- Min Luo (ORCID: https://orcid.org/0000-0003-4670-9712)
- Shengchao Wang (ORCID: https://orcid.org/0000-0002-3504-747X)
- Jiamin Chai
Institutions
- Hubei University of Medicine (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-08
- DOI
- https://doi.org/10.3389/fimmu.2025.1645909
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Hubei Province
- Special Project of Central Government for Local Science and Technology Development of Hubei Province